A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians

Background. A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed to control epidemic group A meningitis in Africa. Documentation of the safety specifications of the PsA-TT vaccine was warranted, with sufficient exposure to detect potential r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Tapia, Milagritos D., Sow, Samba O., Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Enwere, Godwin C., Paranjape, Gandhali, Hervé, Jacques, Bouma, Enricke, Parulekar, Varsha, Martellet, Lionel, Chaumont, Julie, Plikaytis, Brian D., Tang, Yuxiao, Kulkarni, Prasad S., Hartmann, Katharina, Preziosi, Marie-Pierre
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639507/
https://ncbi.nlm.nih.gov/pubmed/26553682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ626
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados